Topotecan (NSC609699) HCl

Catalog No.S1231 Synonyms: Nogitecan HCl, SKFS 104864A

For research use only.

Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively. Topotecan HCl induces autophagy and apoptosis.

Topotecan (NSC609699) HCl Chemical Structure

CAS No. 119413-54-6

Selleck's Topotecan (NSC609699) HCl has been cited by 40 publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Other Topoisomerase Products

Biological Activity

Description Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively. Topotecan HCl induces autophagy and apoptosis.
Features Topotecan is a water-soluble derivative of camptothecin.
Targets
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
In vitro

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells NIm4[WlEgXSxdH;4bYPDqGG|c3H5 MWm3NkBp NHG1S3NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJIlkPTB;MTDuUS=> NHvo[449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO3NVE5Oyd-MkCzO|EyQDN:L3G+
human Bel7402 cells MXHDfZRwfG:6aXRCpIF{e2G7 NVu1UHRLQTZiaB?= NH36cpBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBD\Wx5NECyJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5{IH7N NVzVSWF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxOlUyPDRpPkG1NVY2OTR2PD;hQi=>
human HCT8 cells NVLuTZQzS3m2b4TvfIlkyqCjc4PhfS=> NHvzZ2E6PiCq M{PyfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDhiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlUhdk1? NIrlVFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG2OVE1PCd-MUWxOlUyPDR:L3G+
human MCF7 cells MXnDfZRwfG:6aXRCpIF{e2G7 M2K1PFk3KGh? MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT64JI5O M{[xU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MU[1NVQ1Lz5zNUG2OVE1PDxxYU6=
human A549 cells M3XtfGN6fG:2b4jpZ:Kh[XO|YYm= NUP4OWI2QTZiaB?= MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Mz6yJI5O NXvzPIFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxOlUyPDRpPkG1NVY2OTR2PD;hQi=>
human colon carcinoma SW620 cell NWXacmdFS3m2b4TvfIlkyqCjc4PhfS=> Ml3PR5l1d3SxeHnjJJBwfGWwdHnheIlwdiCxZjDUc5BwfGWlYX6gLHRRMSCkeTD0bIUh[2:vcH;1coQhcW5iaIXtZY4h[2:ub36gZ4Fz[2mwb33hJHNYPjJyIHPlcIwhdGmwZTygTWM2OD1|LkKgcm0> M3v6c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEC4O|A4Lz5zMkSwPFcxPzxxYU6=
human MESSA cells MVrDfZRwfG:6aXRCpIF{e2G7 MV:3NkBp NWrjTpc3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVU1GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwQVQhdk1? NUXZUlZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOFE3PzRpPkKxN|QyPjd2PD;hQi=>
human BGC823 cells MkXJR5l1d3SxeHnjxsBie3OjeR?= MYC5OkBp MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20MlMhdk1? MonCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzNkWxOFQoRjF3MU[1NVQ1RC:jPh?=
human Ketr3 cells NXrMU|B{S3m2b4TvfIlkyqCjc4PhfS=> MU[5OkBp M4\leWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmfHJ|IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE46KG6P M{e3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MU[1NVQ1Lz5zNUG2OVE1PDxxYU6=
LOX cells NXKxfVJbS3m2b4TvfIlkyqCjc4PhfS=> MVLDfZRwfG:6aXPpeJkhf2G|IHTleIVzdWmwZXSgbY4hfmm2cn:gbY4hVE:[IHPlcIx{KCivZXzhco9u[Slib3[gbJVu[W5idIXtc5Ih[2WubDDsbY5meyCkeTD1d4lv\yCPVGSgZZN{[XluIFnDOVA:PSCwTR?= M1PmUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd6NUOzN|EoRjd6NUOzN|E9N2F-
human A549 cells Ml\PSpVv[3Srb36gZZN{[Xl? M{LJPVQhcA>? MWfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02KG6P MknDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{MEe3OFgoRjF6MkC3O|Q5RC:jPh?=
human H69 cells MlPZR5l1d3SxeHnjxsBie3OjeR?= MXm3NkBp MknYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFY6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OD14IH7N MlryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|NEG2O|QoRjJzM{SxOlc1RC:jPh?=
human A2780 cells Mn3rR5l1d3SxeHnjxsBie3OjeR?= NYjVUlIxPzJiaB?= MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDhcJBp[TWkZYThN{BqdnSnZ4LpckBie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;NjDuUS=> MnOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
human LNCAP cells NVvFVlBHS3m2b4TvfIlkyqCjc4PhfS=> MoeyO|IhcA>? M4KxeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME25JI5O M3i2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
human HOP62 cells MmrUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NILLXZpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJV1B4MjDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFnDOVA:OTBibl2= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyOUK3PUc,OjV7MEmyO|k9N2F-
human MCF7 cells NUHYPFB1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3rHdGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P MnnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MEmyO|koRjJ3OUC5Nlc6RC:jPh?=
human UACC62 cells MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXLWOnJUT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQ{[yJINmdGy|IHL5JIZqfmVvZH;z[UBoem:5dHigbY5pcWKrdHnvckBie3OjeTygTWM2OD1zMDDuUS=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyOUK3PUc,OjV7MEmyO|k9N2F-
human DU145 cells NE\wV3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLBb|NsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDJR|UxRTFyIH7N NYPQeJBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NFkzPzlpPkK1PVA6Ojd7PD;hQi=>
LoVo cell line MYrDfZRwfG:6aXRCpIF{e2G7 MYrDfZRwfG:6aXOgdI91\W62aXH0bY9vKG:oIGTvdI91\WOjbjCoWHAqKGK7IITo[UBkd22yb4Xu[EBqdiBqaIXtZY4h[2:ub4LlZ5RidCClYX7j[ZIhVG:YbzDj[YxtKGyrbnWsJGlEPTB;MUGuOkBvVQ>? NELPUYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkSwPFcxPyd-MUK0NFg4ODd:L3G+
human lymphoblast tumor cell line RPM18402 M2DzRWN6fG:2b4jpZ:Kh[XO|YYm= Mk\iR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJlueGixYnzhd5QhfHWvb4KgZ4VtdCCuaX7lJHJRVTF6NECyMEBKSzVyPUGyJI5O M4[1TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{M{myO|Q2Lz5zMkO5Nlc1PTxxYU6=
human HL60 cells NUO1NXpGTnWwY4Tpc44h[XO|YYm= MlPRRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDifUBUWkJibXX0bI9lNCCLQ{WwQVEzKG6P M376TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUSxOFg{Lz5zOUW0NVQ5OzxxYU6=
human A375 cells NV2yT3VCS3m2b4TvfIlkyqCjc4PhfS=> Moi4O|IhcA>? Mn;6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;MUOgcm0> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
COR-L23/P cell MnnHR5l1d3SxeHnjxsBie3OjeR?= M2ryR2N6fG:2b4jpZ4l1gSCvZXHzeZJm\CC3c3nu[{B1cGViQ1;SMWwzOyCyYYLlcpRidCBqQ1;SMWwzOy:SKTDoeY1idiCwb36gd41idGxiY3XscEBtfW6pIHPhdoNqdm:vYTDj[YxtKGyrbnWsJGlEPTB;MUOuNkBvVQ>? MorMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF6ME[3NlQoRjFzOEC2O|I1RC:jPh?=
human NCI-H460 cells NIrONYRRem:uaX\ldoF1cW:wIHHzd4F6 NH\DNVE4OiCq M{DvS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINwfWy2ZYKgZ492dnSncjDhcoFtgXOrczygTWM2OD1zNjDuUS=> NXvCXodTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFM{PjlpPkKxO|g{OzZ7PD;hQi=>
human MOLT4 cells NGDmXI5EgXSxdH;4bYPDqGG|c3H5 M3vnSFczKGh? MmPWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUW9NXDRiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xPUBvVQ>? NEm1O409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFczPSd-MkS5NFA4OjV:L3G+
human LoVo cells NIO1OWZEgXSxdH;4bYPDqGG|c3H5 MnixO|IhcA>? NW\KNY0yS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVG:YbzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIxKG6P MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN5MUG4N{c,OjB|N{GxPFM9N2F-
RPM18402 tumor cell line MkfyVJJwdGmoZYLheIlwdiCjc4PhfS=> MkjER49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IHPlcIwheHKxbHnm[ZJifGmxbjDpckBTWE1zOESwNkB1fW2xcjDj[YxtKGyrbnWsJGlEPTB;MkCgcm0> M{CwTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NEiyPVI6Lz5zNUS4NlkzQTxxYU6=
human SN12C cells NEDvcXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnLIS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV24yOkNiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVIxKG6P M4XGSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUC5Nlc6Lz5{NUmwPVI4QTxxYU6=
human RPMI8226 cells Moe4R5l1d3SxeHnjxsBie3OjeR?= MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ{NjDj[YxteyCkeTDNWHQhdWW2aH;kMEBKSzVyPUKxJI5O MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTBzMkm5Okc,OTlyMUK5PVY9N2F-
HT-29 cells MVHDfZRwfG:6aXRCpIF{e2G7 NVT4d3prS3m2b4TvfIlkcXS7IIfhd{Bl\XSncn3pcoVlKGmwII\peJJwKGmwIFjUMVI6KGOnbHzzLINwdG:wKTDv[kBpfW2jbjD0eY1weiClZXzsJIxqdmW|IHL5JJV{cW6pIF3UWEBie3OjeTygTWM2OD1{NTDuUS=> M1PhPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd6NUOzN|EoRjd6NUOzN|E9N2F-
SK-BR-3 cells MmDIR5l1d3SxeHnjxsBie3OjeR?= MmLjTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsJIxqdmViKGPLMWJTNTNrLDDJR|UxRTJ4IH7N NHGxdY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
HeLa cells M3zJ[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUe0bW9kT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSHXMZUBk\WyuczDh[pRmeiB2IHThfZMtKEeLNUC9N|Ahdk1? NV7lTZoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVg2QDJpPkG3OFE5PTh{PD;hQi=>
UACC 62 cells MXPDfZRwfG:6aXRCpIF{e2G7 Mo\2WIV{fGWmIHnuJJZqfHKxIH\vdkBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB1fW2xcjDj[YxtKGyrbnWgWWFESyB4MjCocYVt[W6xbXGpMEBIUTVyPUOwJI5O M3HIUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyN{G0OVAzLz5zMEexOFUxOjxxYU6=
human HCT116 cells Mn3BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NU[4W3R5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IHL5JIZqfmVvZH;z[UBoem:5dHigbY5pcWKrdHnvckBie3OjeTygS2k2OD1|MDDuUS=> NH7ifYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmwPVI4QSd-MkW5NFkzPzl:L3G+
human lung cancer cell line (H128) NVTFd2c5S3m2b4TvfIlkyqCjc4PhfS=> MWXJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDseY5oKGOjbnPldkBk\WyuIHzpcoUhMEhzMkipMEBKSzVyPUOxJI5O NWT6dld1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
human MES-SA/Dx5 cells MUPDfZRwfG:6aXRCpIF{e2G7 NYnEVFJvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDNSHIyKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2zN{BvVQ>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
human A2780 cells NWqzXGd4S3m2b4TvfIlkyqCjc4PhfS=> NFrHUnA4OiCq MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOzJI5O MnvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NlUoRjJ2OUCwO|I2RC:jPh?=
human MDA-MB-435 cells M3m1bmN6fG:2b4jpZ:Kh[XO|YYm= NVrWS3BEPzJiaB?= MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF0{PCCwTR?= NVq3d245RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OlcxOTlpPkKyPFY4ODF7PD;hQi=>
human stomach cancer cell line (MKN45) NHvNUXREgXSxdH;4bYPDqGG|c3H5 M1HxfGlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJN1d22jY3igZ4Fv[2W{IHPlcIwhdGmwZTCoUWtPPDVrLDDJR|UxRTN6IH7N M{PxU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human KB3-1 cells MX\DfZRwfG:6aXRCpIF{e2G7 NHPX[IhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSjNvMTDj[YxteyCjZoTldkBOXFRiYYPzZZktKEmFNUC9OFAhdk1? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh{OUOzOEc,OTh6MkmzN|Q9N2F-
mouse P388 cells NVexXGF{S3m2b4TvfIlkyqCjc4PhfS=> MkPrR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVFM5QCClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NEWgcm0> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh{OUOzOEc,OTh6MkmzN|Q9N2F-
A427 human lung carcinoma NVzWNVJbWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mn24RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgcYVie3W{ZXSgZYdicW6|dDDBOFI4KGi3bXHuJIx2dmdiY3HyZ4lvd22jLDDJR|UxRTR7IH7N MnnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTh5NkGxNUc,QTh5NkGxNVww[T5?
human U251 cells NV7JdZRQTnWwY4Tpc44h[XO|YYm= M1Xzc|YuOjRiaB?= MUHJcohq[mm2aX;uJI9nKHSxcH;pd49u\XKjc3WtNUBqdiCqdX3hckBWOjVzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhcHmyb4jpZU1qdmS3Y3XkJGhKTi1zYXzwbIEh[WOldX31cIF1cW:wIHnuJI52[2ynYYKg[Zh1emGldDDh[pRmeiB4IITvJFI1KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{NCCHQ{WwQVU1KG6P NXjOfXY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNFU3OTJpPkKyN|A2PjF{PD;hQi=>
human colon cancer cell line (WiDr) NGH2T29EgXSxdH;4bYPDqGG|c3H5 MV;JckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubDDsbY5mKCiZaVTyLUwhUUN3ME21OkBvVQ>? M2CyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human HepG2 cells MX\DfZRwfG:6aXRCpIF{e2G7 NGK0V4g1KGSjeYO= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPU[wJI5O Mo\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUS5NFYoRjF6NUW0PVA3RC:jPh?=
human KB cells MUfDfZRwfG:6aXRCpIF{e2G7 MkC1O|IhcA>? MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUC9OlIvPSCwTR?= NHvHcGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPFQ2Pid-MkWwNFg1PTZ:L3G+
human HCT8 cells NYHw[YFsS3m2b4TvfIlkyqCjc4PhfS=> M3fLWVMh\GG7cx?= NVvpZZc5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWODDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6P MkPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|OUK1OFUoRjJyM{myOVQ2RC:jPh?=
human GBM2 cells MWHQdo9tcW[ncnH0bY9vKGG|c3H5 NWnDSXRQPzJiaB?= NV;teJhVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0zKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:OC5zMzFOwG0> NHPPVm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1OVU{Oid-Mk[zOVU2OzJ:L3G+
SK-MEL-2 cells M2LlTGN6fG:2b4jpZ:Kh[XO|YYm= MX:3NkBp NXPjZpJWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTVXMMVIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTBwMUSg{txO NGrI[Ww9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0NVY4PCd-MkGzOFE3PzR:L3G+
human IGROV1 cells MoLGR5l1d3SxeHnjxsBie3OjeR?= NXrXWnFIPzJiaB?= Ml;JR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTWdTV1ZzIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2wMlE3KM7:TR?= MkjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|NEG2O|QoRjJzM{SxOlc1RC:jPh?=
human U87 cells MYHQdo9tcW[ncnH0bY9vKGG|c3H5 NVLSfnloPDhiaB?= MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6NzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMU[g{txO NYTaW|U4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NlY5OThpPkK0PFI3QDF6PD;hQi=>
human HT1080 cells Mn20VJJwdGmoZYLheIlwdiCjc4PhfS=> NWDUZmp7PDhiaB?= M1LreWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSxNFgxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OC5zODFOwG0> NV\3NVBERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NFg5OTVpPkK2OFA5QDF3PD;hQi=>
human Hep3B cells MWDQdo9tcW[ncnH0bY9vKGG|c3H5 NIHS[FQ4OiCq MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincEPCJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC[VGSgZZN{[XluIFfJOVA:OC5{MjFOwG0> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd7Nkm1Okc,OTl5OU[5OVY9N2F-
human GBM3 cells M4XPe3Bzd2yrZnXyZZRqd25iYYPzZZk> MU[3NkBp NIPBcIVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfCUVMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHdUXC1zIH3leIhw\CxiSVO1NF0xNjN6IN88US=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3NUWzNkc,OjZ|NUW1N|I9N2F-
human KBVIN cells M4rCTWN6fG:2b4jpZ:Kh[XO|YYm= MlXTO|IhcA>? M2HYbWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDXkmQIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR|OEe2PUc,OjV2M{i3Olk9N2F-
human GBM1 cells NUfkeXo5WHKxbHnm[ZJifGmxbjDhd5NigQ>? MYq3NkBp M3XLWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVAvPDZizszN NFm5PFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1OVU{Oid-Mk[zOVU2OzJ:L3G+
human U937 cells MVHDfZRwfG:6aXRCpIF{e2G7 MljFOFghcA>? M2jUU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMh\XiycnXzd4lv\yCyNUOgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[Xli78{MJGlEPTB;MT6xJO69VQ>? NF3CNWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUexOVMyQSd-MUm3NVU{OTl:L3G+
Caco2 MoTIR5l1d3SxeHnjbZR6KGG|c3H5 NGTFOZYzPCCqcoO= NEL0dnVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[WOxMjDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF7zszNMi=> MlvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
Jurkat NH7IVJdEgXSxdH;4bYNqfHliYYPzZZk> M3PoXlI1KGi{cx?= M4HNPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGp2emujdDDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTJ5zszNMi=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl6MEGxPEc,OjR7OECxNVg9N2F-
A375 NGradHpEgXSxdH;4bYNqfHliYYPzZZk> MXeyOEBpenN? MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xOlLPxE1w M1[xelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
HeLa M2fmWGN6fG:2b4jpZ4l1gSCjc4PhfS=> NIr1d4IzPCCqcoO= MnTFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuN|jPxE1w NIHqZm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
MDA-MB-231 MoKyR5l1d3SxeHnjbZR6KGG|c3H5 NWfrPWVFOjRiaILz NEfMfFhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD60O|PPxE1w M3jyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
NCI-H460 MmDRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MoXCNUBpeg>? NXjETo5xSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkB{cG:{dDD0[ZJuKGW6cH;zeZJmKG[xcjCxJIhzKG2nYYP1doVlKGGodHXyJFczKGi{czDpckBlenWpLX\y[YUhdWWmaYXtMEBKSzVyPUCuOlHPxE1w NETPfog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzNFczOCd-MUm1N|A4OjB:L3G+
HCT8 NWCzfJhKSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NUPPOWpvPDhiaILz M1XhbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUPEBk\WyuczDh[pRmeiB2ODDodpMh[nliQ1PLPEBie3OjeTygTWM2OD1zLki3Oe69VS5? M4\ZR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEixN|k2Lz5{NUS4NVM6PTxxYU6=
KB NHzXZ2VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVG0PEBpenN? NIXubHpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR|UxRTJwMkiy{txONg>? NGfDRos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4NVM6PSd-MkW0PFE{QTV:L3G+
SGC7901 M2flRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVPidGlLPDhiaILz MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOJQ{e5NFEh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFPDT|gh[XO|YYmsJGlEPTB;Mj6yPVLPxE1w M3TkVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEixN|k2Lz5{NUS4NVM6PTxxYU6=
HepG2 MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVG0PEBpenN? MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR|UxRTRwMkC4{txONg>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6MUO5OUc,OjV2OEGzPVU9N2F-
MDA-MB-231 NYfXXXdqSXCxcITvd4l{KGG|c3H5 NVjDeGl[UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJJA2OyCyaH;zdIhwenmuYYTpc44h[XRiU3XyNVUh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>? NFTueHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
HeLa NU\sOoNOSXCxcITvd4l{KGG|c3H5 NGPaW28xNjhidH:gNU43KHWP NVjR[GJlOjRiaILz NYLIVoVPUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSG5CKHO7boTo[ZNqeyCjdDCwMlghfG9iMT62JJVOKGGodHXyJFI1KGi{czDifUBDemSXIIP0ZYlvcW6pLXLhd4VlKEWOSWPB M4KwNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
MDA-MB-231 M{PsWGFxd3C2b4Ppd{Bie3OjeR?= MYewMlghfG9iMT62JJVO MV[yOEBpenN? Ml3sTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTE6DIIP5cpRp\XOrczDheEAxNjhidH:gNU43KHWPIHHmeIVzKDJ2IHjyd{BjgSCEcnTVJJN1[WmwaX7nMYJie2WmIFXMTXNC MmOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
A375 MYHBdI9xfG:|aYOgZZN{[Xl? NVPqemhmOC56IITvJFEvPiC3TR?= NFzMcogzPCCqcoO= NH3UbmdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFGzO|Uh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDEUmEhe3mwdHjld4l{KGG2IECuPEB1dyBzLk[geW0h[W[2ZYKgNlQhcHK|IHL5JGJz\FVic4ThbY5qdmdvYnHz[YQhTUyLU1G= NIfXVIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
Caco2 MoO4RZBweHSxc3nzJIF{e2G7 NH7SUXoxNjhidH:gNU43KHWP NV3TR3VXOjRiaILz MnXaTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCFYXPvNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFTORUB{gW62aHXzbZMh[XRiMD64JJRwKDFwNjD1UUBi\nSncjCyOEBpenNiYomgRpJlXSC|dHHpcolv\y2kYYPl[EBGVEmVQR?= NUfG[VlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PFAyOThpPkK0PVgxOTF6PD;hQi=>
A375 M3;Td2Fxd3C2b4Ppd{Bie3OjeR?= NXT5WIl2UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDBN|c2KGOnbHzzJIF{e2W|c3XkJIF{KHB3MzDwbI9{eGixconsZZRqd25iYYSgV4VzOTViYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?= Mnj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
TC32 MlrTdWhVWyCjc4PhfS=> NUjrOHVseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= NHXaRoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY MlXkdWhVWyCjc4PhfS=> NVXXS4k3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 MnHGdWhVWyCjc4PhfS=> M4HCZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NGLYXoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MUXxTHRUKGG|c3H5 MknOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? M1;ORlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MlXUdWhVWyCjc4PhfS=> NFPveI5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NGTjOpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NV\aRWZCeUiWUzDhd5NigQ>? NYr4[WxMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz NVnSfYhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MYrxTHRUKGG|c3H5 NWG5[|J2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> NUPv[oE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 NHvjZ4xyUFSVIHHzd4F6 M3HidpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= M{XNe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH M164WJFJXFNiYYPzZZk> M{jESJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz M1\wT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NX;ZeYtzeUiWUzDhd5NigQ>? MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NXTy[pcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MnjKdWhVWyCjc4PhfS=> NGnvN4NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 NEXzTHdyUFSVIHHzd4F6 M1LPTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= Mo\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 NFXwfmVyUFSVIHHzd4F6 NV\IU4k{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= M{DvTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NFrvblRyUFSVIHHzd4F6 MmjDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MnXMdWhVWyCjc4PhfS=> MmfvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MlOxdWhVWyCjc4PhfS=> MmS1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MVLxTHRUKGG|c3H5 M1rFRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MnfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MnHSdWhVWyCjc4PhfS=> M2\pSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>? M2DneFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NFLaPHZyUFSVIHHzd4F6 NI\4eJNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? NVLmW4t4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC MVrxTHRUKGG|c3H5 Ml\SdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>? MnTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 MUXxTHRUKGG|c3H5 M3PXfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{ MkL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MoXHdWhVWyCjc4PhfS=> M{nN[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGxCVi13IHPlcIx{ NUW3NHJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY M4nJc5FJXFNiYYPzZZk> MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz NH3lNJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 M{jIWJFJXFNiYYPzZZk> NVe2VVZ4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NF7PUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 M2L1OpFJXFNiYYPzZZk> M3ToV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? MnXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M2O5fpFJXFNiYYPzZZk> Mo\ydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM> M1L2TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32 NYW3U5lveUiWUzDhd5NigQ>? M3;RfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) NVqzXWh7eUiWUzDhd5NigQ>? MkPZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM> NXi0OJpLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS M17SfpFJXFNiYYPzZZk> MnzxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{ MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 NFjabm9yUFSVIHHzd4F6 NWC5fnVOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MX;xTHRUKGG|c3H5 NGLCR|NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=> Mmj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 M{TYbZFJXFNiYYPzZZk> NYXlXFVieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NWrWXItERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 NV[wSVRTeUiWUzDhd5NigQ>? M3q0OZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM> NHfESGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 M1vlbJFJXFNiYYPzZZk> Mlu4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{ MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NH7teZpyUFSVIHHzd4F6 NUXzXpFueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH M3jQbpFJXFNiYYPzZZk> MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{ NGfMOpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH NIq4OnlyUFSVIHHzd4F6 MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? Mlu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NGTid25yUFSVIHHzd4F6 M2nkRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= NXHVVHd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Daoy NGPuPZNyUFSVIHHzd4F6 MlrHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohV3K2aH;nc45idCB|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBF[W:7IHPlcIx{ MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 MWjxTHRUKGG|c3H5 MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR|MzKGOnbHzz NVrOfVU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 NYGwdYFNeUiWUzDhd5NigQ>? NVvJOJBleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| M3TuSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MkL3dWhVWyCjc4PhfS=> NUC1NlNzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MoS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NV\VUW9[eUiWUzDhd5NigQ>? NEnKZVRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFKGIHPlcIx{ NX:2WHJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Assay
Methods Test Index PMID
Western blot LC3 / p62 ; p53 / sesn2 / p-AMPK 23024792
Growth inhibition assay Cell viability 28544814
In vivo Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: MCF-7 Luc and DU-145 Luc cells
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96 hours
  • Method:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.

Animal Research:

[1]

  • Animal Models: Mice with MCF-7 Luc or DU-145 Luc cells
  • Dosages: 0.25 mg/mL
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

DMSO 91 mg/mL
(198.72 mM)
Water 91 mg/mL
(198.72 mM)
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 457.91
Formula

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04455139 Recruiting Drug: Topotecan|Drug: Melphalan Eye Cancer Retinoblastoma Prof. Beck Popovic Maja|University of Lausanne Hospitals November 15 2021 Phase 2
NCT05083000 Recruiting Drug: Topotecan COVID-19 Respiratory Infection National University Hospital Singapore|Christian Medical College Vellore India August 16 2021 Phase 1
NCT04156347 Recruiting Drug: Episcleral Topotecan Retinoblastoma Targeted Therapy Technologies LLC June 16 2021 Phase 1
NCT04428879 Recruiting Drug: Topotecan Episcleral Plaque Retinoblastoma The Hospital for Sick Children June 16 2020 Phase 1
NCT03927274 Recruiting Drug: Topotecan Glioma of Brain H. Lee Moffitt Cancer Center and Research Institute June 20 2019 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

Answer:
Topotecan HCl is generally prepared by Saline for I.P. administration.

Tags: buy Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl supplier | purchase Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl cost | Topotecan (NSC609699) HCl manufacturer | order Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl distributor